Apoptosis in Leukemias: Regulation and Therapeutic Targeting

  • Ismael Samudio
  • Marina Konopleva
  • Bing Carter
  • Michael Andreeff
Part of the Cancer Treatment and Research book series (CTAR, volume 145)


Nearly 25 years after the seminal publication of John Foxton Kerr that first described apoptosis, the process of regulated cell death, our understanding of this basic physiological phenomenon is far from complete [39]. From cardiovascular disease to cancer, apoptosis has assumed a central role with broad ranging therapeutic implications that depend on a complete understanding of the molecular events involved in orchestrating cellular demise. More than 145,301 (as of April 2008) published works on this subject have increased our understanding of this process, yet have also identified an incredibly complex regulatory system that is critical for development and is at the core of many diseases, challenging scientists and clinicians to step into its molecular realm and modulate its circuitry for therapeutic purposes. This chapter will review our understanding of the molecular circuitry that controls apoptosis in leukemia and the pharmacological manipulations of this pathway that may yield therapeutic benefit.


Death Induce Signaling Complex Require Caspase Activation Death Induce Signaling Complex Formation Sensitize Leukemia Cell Primary Leukemia Sample 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Adida C, Recher, C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111:196–203.PubMedGoogle Scholar
  2. 2.
    Andreeff M, Zeng Z, Tabe Y, et al. Microenvironment and leukemia: Ying and Yang. Ann Hematol. 2008;87:S94–S98.Google Scholar
  3. 3.
    Asakura T, Ohkawa K. Chemotherapeutic agents that induce mitochondrial apoptosis. Curr Cancer Drug Targets. 2004;4:577–590.PubMedGoogle Scholar
  4. 4.
    Baumgartner B, Weber M, Quirling M, et al. Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia. 2002;16;2062–2071.PubMedGoogle Scholar
  5. 5.
    Brookes PS, Morse K, Ray D, et al. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res. 2007;67;1793–1802.PubMedGoogle Scholar
  6. 6.
    Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9;33–41.PubMedGoogle Scholar
  7. 7.
    Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma. 1995;17;13–18.PubMedGoogle Scholar
  8. 8.
    Bueso-Ramos CE, Rocha FC, Shishodia S, et al. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol. 2004;35:246–253.PubMedGoogle Scholar
  9. 9.
    Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993;82:2617–2623.PubMedGoogle Scholar
  10. 10.
    Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091–3096.PubMedGoogle Scholar
  11. 11.
    Carter BZ, Gronda M, Wang Z, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood. 2005;105:4043–4050.PubMedGoogle Scholar
  12. 12.
    Carter BZ, Kornblau SM, Tsao T, et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or survivin does not affect cell survival or prognosis. Blood. 2003;102:4179–4186.PubMedGoogle Scholar
  13. 13.
    Carter BZ, Mak D, Schober WD, et al. Regulation of survivin expression through bcr-abl/MAPK cascade: targeting survivin overcomes Imatinib resistance and increases Imatinib sensitivity in Imatinib responsive CML cells. Blood. 2006:107:1555–1563.PubMedGoogle Scholar
  14. 14.
    Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006;108:630–637.PubMedGoogle Scholar
  15. 15.
    Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008;111:3742–3750.PubMedGoogle Scholar
  16. 16.
    Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97:2784–2790.PubMedGoogle Scholar
  17. 17.
    Carter BZ, Milella M, Tsao T, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003;17:2081–2089.PubMedGoogle Scholar
  18. 18.
    Certo M, Moore VG, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9:351–365.PubMedGoogle Scholar
  19. 19.
    Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol. 2004;31:119–128.PubMedGoogle Scholar
  20. 20.
    Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005;24:3411–3422.PubMedGoogle Scholar
  21. 21.
    Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7:313–319.PubMedGoogle Scholar
  22. 22.
    Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–1014.PubMedGoogle Scholar
  23. 23.
    Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001;3:173–182.PubMedGoogle Scholar
  24. 24.
    Deng X, Gao F, Flagg T, Anderson J, May WS. Bcl2's Flexible loop domain regulates p53 binding and survival. Mol Cell Biol. 2006;26:4421–4434.PubMedGoogle Scholar
  25. 25.
    Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100:194–199.PubMedGoogle Scholar
  26. 26.
    Faderl S, Kantarjian HM, Estey E, et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000;89:1976–1982.PubMedGoogle Scholar
  27. 27.
    Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biological activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009;113:1504–1512.Google Scholar
  28. 28.
    Fleischer A, Rebollo A, Ayllon V. BH3-only proteins: the lords of death. Arch Immunol Ther Exp (Warsz.). 2003;51:9–17.Google Scholar
  29. 29.
    Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–1312.PubMedGoogle Scholar
  30. 30.
    Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307.PubMedGoogle Scholar
  31. 31.
    Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA. 2004;101:15313–15317.PubMedGoogle Scholar
  32. 32.
    Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci. 2004;61:822–842.PubMedGoogle Scholar
  33. 33.
    Hu G, Zhang W, Deisseroth AB. P53 gene mutations in acute myelogenous leukaemia. Br J Haematol. 1992;81:489–494.PubMedGoogle Scholar
  34. 34.
    Invernizzi R, Travaglino E, Lunghi M, et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma. 2004;45:2229–2237.PubMedGoogle Scholar
  35. 35.
    Jia L, Coward LC, Kerstner-Wood CD, et al. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol. 2008;61:63–73.PubMedGoogle Scholar
  36. 36.
    Johnston JB, Kabore AF, Strutinsky J, et al. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene. 2003;22:8356–8369.PubMedGoogle Scholar
  37. 37.
    Jones DT, Ganeshaguru K, Mitchell WA, et al. Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand. Br J Haematol. 2003;121:713–720.PubMedGoogle Scholar
  38. 38.
    Kamer I, Sarig R, Zaltsman Y, et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell. 2005;122:593–603.PubMedGoogle Scholar
  39. 39.
    Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257.PubMedGoogle Scholar
  40. 40.
    Kim TS, Yun BY, Kim IY. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol. 2003;66:2301–2311.PubMedGoogle Scholar
  41. 41.
    Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood. 2008;111:3211–3219.PubMedGoogle Scholar
  42. 42.
    Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003;46:4259–4264.PubMedGoogle Scholar
  43. 43.
    Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood. 2006a;108:993–1000.PubMedGoogle Scholar
  44. 44.
    Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle. 2006b;5:2778–2786.PubMedGoogle Scholar
  45. 45.
    Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150–3159.PubMedGoogle Scholar
  46. 46.
    Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008a;112:2886–2895.PubMedGoogle Scholar
  47. 47.
    Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. The CDK1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009;100:1128–1136.Google Scholar
  48. 48.
    Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008b;22:1728–1736.PubMedGoogle Scholar
  49. 49.
    Kong G, Wang D, Wang H, et al. Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia. 2008;22:1258–1262.PubMedGoogle Scholar
  50. 50.
    Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10:375–388.PubMedGoogle Scholar
  51. 51.
    Konopleva M, Tsao T, Estrov Z, et al. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res. 2004;64:7927–7935.PubMedGoogle Scholar
  52. 52.
    Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008;68:3413–3420.PubMedGoogle Scholar
  53. 53.
    Koschmieder S, D'Alo F, Radomska H, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007;110:3695–3705.PubMedGoogle Scholar
  54. 54.
    Kress CL, Konopleva M, Martinez-Garcia V, et al. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS ONE. 2007;2:e559.PubMedGoogle Scholar
  55. 55.
    Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2007;140:181–190.PubMedGoogle Scholar
  56. 56.
    Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525–535.PubMedGoogle Scholar
  57. 57.
    Lacasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann NY Acad Sci. 2005;1058:215–234.PubMedGoogle Scholar
  58. 58.
    Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003;63:8118–8121.PubMedGoogle Scholar
  59. 59.
    Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates T. Science. 2004;305:1471–1474.PubMedGoogle Scholar
  60. 60.
    Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 2001;412:95–99.PubMedGoogle Scholar
  61. 61.
    Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003;101:4078–4087.PubMedGoogle Scholar
  62. 62.
    Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147–157.PubMedGoogle Scholar
  63. 63.
    Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 1999;6:516–524.PubMedGoogle Scholar
  64. 64.
    MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett. 2003;139:89–97.PubMedGoogle Scholar
  65. 65.
    MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002;21:6809–6818.PubMedGoogle Scholar
  66. 66.
    Markey M, Berberich SJ. Full-length hdmX transcripts decrease following genotoxic stress. Oncogene. 2008;27:6657–6666.PubMedGoogle Scholar
  67. 67.
    McStay GP, Clarke SJ, Halestrap AP. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem J. 2002;367:541–548.PubMedGoogle Scholar
  68. 68.
    Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81:151–157.PubMedGoogle Scholar
  69. 69.
    Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001–1008.PubMedGoogle Scholar
  70. 70.
    Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem. 1998;273:2926–2930.PubMedGoogle Scholar
  71. 71.
    Nikolovska-Coleska Z, Xu L, Hu Z, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004;47:2430–2440.PubMedGoogle Scholar
  72. 72.
    Okamoto K, Kashima K, Pereg Y, et al. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol. 2005;25:9608–9620.PubMedGoogle Scholar
  73. 73.
    Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681.PubMedGoogle Scholar
  74. 74.
    Oost TK, Sun C, Armstrong RC, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem. 2004;47:4417–4426.PubMedGoogle Scholar
  75. 75.
    Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307:1101–1104.PubMedGoogle Scholar
  76. 76.
    Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426:671–676.PubMedGoogle Scholar
  77. 77.
    Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006;66:3169–3176.PubMedGoogle Scholar
  78. 78.
    Pazgier M, Liu M, Zou G, et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA. 2009;106:4665–4670.PubMedGoogle Scholar
  79. 79.
    Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003;10:26–35.PubMedGoogle Scholar
  80. 80.
    Pop C, Timmer J, Sperandio S, Salvesen GS. The apoptosome activates caspase-9 by dimerization. Mol Cell. 2006;22:269–275.PubMedGoogle Scholar
  81. 81.
    Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell. 1999;3:287–296.PubMedGoogle Scholar
  82. 82.
    Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408–418.PubMedGoogle Scholar
  83. 83.
    Riccioni R, Pasquini L, Mariani G, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica. 2005;90:612–624.PubMedGoogle Scholar
  84. 84.
    Saelens X, Festjens N, Vande WL, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23:2861–2874.PubMedGoogle Scholar
  85. 85.
    Salvesen GS, Dixit VM. Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA. 1999;96:10964–10967.PubMedGoogle Scholar
  86. 86.
    Samudio I, Konopleva M, Pelicano H, et al. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol. 2006;5, 1182–1193.Google Scholar
  87. 87.
    Schimmer AD, Kantarjian H, O'Brien S, et al. A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with refractory hematologic malignancies. Clin Cancer Res. 2008. In press.Google Scholar
  88. 88.
    Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;5:25–35.PubMedGoogle Scholar
  89. 89.
    Schottelius A, Brennscheidt U, Ludwig WD, Mertelsmann RH, Herrmann F, Lubbert M. Mechanisms of p53 alteration in acute leukemias. Leukemia. 1994;8:1673–1681.PubMedGoogle Scholar
  90. 90.
    Seliger B, Papadileris S, Vogel D, et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol. 1996;57:230–240.PubMedGoogle Scholar
  91. 91.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med. 2005;16:1125–1138.PubMedGoogle Scholar
  92. 92.
    Sheikh MS, Huang Y. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets. 2004;4:97–104.PubMedGoogle Scholar
  93. 93.
    Shiau CW, Huang JW, Wang DS, et al. alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J Biol Chem. 2006;281:11819–11825.PubMedGoogle Scholar
  94. 94.
    Shiau CW, Yang CC, Kulp SK, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005;65:1561–1569.PubMedGoogle Scholar
  95. 95.
    Shiiki K, Yoshikawa H, Kinoshita H, et al. Potential mechanisms of resistance to TRAIL/Apo2L-induced apoptosis in human promyelocytic leukemia HL-60 cells during granulocytic differentiation. Cell Death Differ. 2000;7:939–946.PubMedGoogle Scholar
  96. 96.
    Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834–842.PubMedGoogle Scholar
  97. 97.
    Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem. 2000;275:36152–36157.PubMedGoogle Scholar
  98. 98.
    Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med. 1998;188:211–216.PubMedGoogle Scholar
  99. 99.
    Suh WS, Kim YS, Schimmer AD, et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia. 2003;17:2122–2129.PubMedGoogle Scholar
  100. 100.
    Sun H, Nikolovska-Coleska Z, Chen J, et al. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg Med Chem Lett. 2005;15:793–797.PubMedGoogle Scholar
  101. 101.
    Sun H, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc. 2004;126:16686–16687.PubMedGoogle Scholar
  102. 102.
    Tabe Y, Konopleva M, Kondo Y, et al. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL. Cancer Biol Ther. 2007;6:1967–1977.PubMedGoogle Scholar
  103. 103.
    Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6:1796–1803.PubMedGoogle Scholar
  104. 104.
    Tamm I, Richter S, Oltersdorf D, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10:3737–3744.PubMedGoogle Scholar
  105. 105.
    Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma. 2002;49:141–144.PubMedGoogle Scholar
  106. 106.
    Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol. 2001;3:183–191.PubMedGoogle Scholar
  107. 107.
    Vahsen N, Cande C, Briere JJ, et al. AIF deficiency compromises oxidative phosphorylation. EMBO J. 2004;23:4679–4689.PubMedGoogle Scholar
  108. 108.
    Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–848.PubMedGoogle Scholar
  109. 109.
    Verrier F, Deniaud A, Lebras M, et al. Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene. 2004;23:8049–8064.PubMedGoogle Scholar
  110. 110.
    Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res. 2009;7:1–11.PubMedGoogle Scholar
  111. 111.
    Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 2000;97:7124–7129.PubMedGoogle Scholar
  112. 112.
    Waterhouse NJ, Sedelies KA, Sutton VR, et al. Functional dissociation of DeltaPsim and cytochrome c release defines the contribution of mitochondria upstream of caspase activation during granzyme B-induced apoptosis. Cell Death Differ. 2006;13:607–618.PubMedGoogle Scholar
  113. 113.
    Wei J, Rega MF, Kitada S, et al. Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett. 2009;273:107–113.PubMedGoogle Scholar
  114. 114.
    Wu TY, Wagner KW, Bursulaya B, Schultz PG, Deveraux QL. Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol. 2003;10:759–767.PubMedGoogle Scholar
  115. 115.
    Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia. 2001;15:921–928.PubMedGoogle Scholar
  116. 116.
    Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004;95:777–783.PubMedGoogle Scholar
  117. 117.
    Ye H, Cande C, Stephanou NC, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9:680–684.PubMedGoogle Scholar
  118. 118.
    Zeng Z, Shi Y-X, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215–6224.Google Scholar
  119. 119.
    Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008a;22:808–818.PubMedGoogle Scholar
  120. 120.
    Zhang WG, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008b;100:184–198.PubMedGoogle Scholar
  121. 121.
    Zhao Y, Chaiswing L, Velez JM, et al. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 2005;65:3745–3750.PubMedGoogle Scholar
  122. 122.
    Zhu Y, Swanson BJ, Wang M, et al. Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc Natl Acad Sci USA. 2004;101:7681–7686.PubMedGoogle Scholar
  123. 123.
    Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. A role for proapoptotic BID in the DNA-damage response. Cell. 2005;122:579–591.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ismael Samudio
    • 1
  • Marina Konopleva
    • 2
  • Bing Carter
    • 1
  • Michael Andreeff
    • 3
  1. 1.Section of Molecular Hematology and Therapy, Department of Stem Cell Transplantation and Cellular TherapyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Section of Molecular Hematology and Therapy, Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Blood and Marrow TransplantationUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations